GSK Says US FDA Approves Boostrix for Immunization During Pregnancy
10 October 2022 - 5:48PM
Dow Jones News
By Anthony O. Goriainoff
GSK PLC said Monday that the U.S. Food and Drug Administration
has approved Boostrix for immunization during the third trimester
of pregnancy to help prevent pertussis, or whooping cough, in
infants under two months old.
The U.K.-based maker of cancer and asthma medications said the
vaccine--which is given during pregnancy--passes antibodies to
babies before birth. The vaccine is also indicated against tetanus,
diphtheria and pertussis in individuals aged 10 years and older,
GSK said.
Boostrix is currently approved in more than 80 countries
including most EU countries, as well as Canada, Australia and New
Zealand, as a vaccine for tetanus, diphtheria and pertussis, the
company said.
Write to Anthony O. Goriainoff at
anthony.orunagoriainoff@dowjones.com
(END) Dow Jones Newswires
October 10, 2022 02:33 ET (06:33 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
GSK (NYSE:GSK)
Historical Stock Chart
From Oct 2024 to Nov 2024
GSK (NYSE:GSK)
Historical Stock Chart
From Nov 2023 to Nov 2024
